- Nano cap biotech GeoVax Labs ( NASDAQ: GOVX ) added ~56% on Wednesday after announcing that the U.S. regulators agreed to grant a patent covering its Zika vaccine candidate GEO-ZM02.
- Specifically, the U.S. Patent and Trademark Office (USPTO) has issued the Notice of Allowance in connection with a patent application related to the company's modified vaccinia Ankara (MVA) vector platform.
- The patent cover GeoVax's ( GOVX ) MVA vector that codes for a ZIKV nonstructural (NS1) protein used in GEO-ZM02.
- Zika virus (ZIKV) is endemic in certain parts of the world, leading to microcephaly in babies and the neurodegenerative disease, Guillain- Barre syndrome, in adults.
- With a Strong Buy rating on GeoVax ( GOVX ), Seeking Alpha contributor Terry Chrisomalis argues that the stock indicates "a great speculative biotech play to look into."
For further details see:
GeoVax jumps 56% after Zika vaccine patent